Last reviewed 2026-05-28 · How we verify

Test treatment : V0116 transdermal patch

Pierre Fabre Medicament · Phase 1 active Small molecule ✓ Verified May 2026

Test treatment : V0116 transdermal patch is a Small molecule drug developed by Pierre Fabre Medicament. It is currently in Phase 1 development.

The V0116 transdermal patch was tested in a study involving healthy smokers, comparing its effects to a nicotine transdermal patch. The study, which was completed in 2014, was a bioequivalence study to evaluate the V0116 transdermal patch.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Test treatment : V0116 transdermal patch
Sponsor	Pierre Fabre Medicament
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Nicotine Patch - Bioequivalence Study (PHASE1)
Nicotine Patch Bioequivalence Study (PHASE1)
Nicotine Patch - Multidose Bioequivalence Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Test treatment : V0116 transdermal patch CI brief — competitive landscape report
Test treatment : V0116 transdermal patch updates RSS · CI watch RSS
Pierre Fabre Medicament portfolio CI

Frequently asked questions about Test treatment : V0116 transdermal patch

What is Test treatment : V0116 transdermal patch?

Test treatment : V0116 transdermal patch is a Small molecule drug developed by Pierre Fabre Medicament.

Who makes Test treatment : V0116 transdermal patch?

Test treatment : V0116 transdermal patch is developed by Pierre Fabre Medicament (see full Pierre Fabre Medicament pipeline at /company/pierre-fabre-medicament).

What development phase is Test treatment : V0116 transdermal patch in?

Test treatment : V0116 transdermal patch is in Phase 1.

Manufacturer: Pierre Fabre Medicament — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing